Some doctors say drugs that improve muscle mass could benefit older or infirm people at greater risk of falls and fractures. A higher portion of muscle can also help patients keep weight off for ...

Fund Of The Week quizzes fund managers about how they’re investing your money. If you’d like to suggest which funds you want ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Discover the latest strategic moves of Duquesne Family Office's $3.72B portfolio, including new stakes, increased investments ...

Altimmune's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH. Learn why ALT ...

Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...

Eli Lilly should easily beat the market again in 2025, as it did in 2024. Summit Therapeutics awaits a potentially huge ...

We recently published a list of the 10 Best Drug Stocks to Buy Now. In this article, we are going to take a look at where Eli ...

Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for ...

Pharmaceutical giant Novo Nordisk (NYSE: NVO) released its fourth-quarter and full-year earnings report on Feb. 5. Here are two important insights from that call that should excite investors about ...

The recent surge has been due to the tremendous growth Lilly has achieved due to its highly popular GLP-1 drugs, including ...